MiMedx Group, Inc. (MDXG) Bundle
A Brief History of MiMedx Group, Inc.
MiMedx Group, Inc. (MDXG) has established itself as a leader in the regenerative medicine sector, specializing in the development and commercialization of allograft products for wound care and surgical applications. As of 2024, the company has demonstrated significant financial growth and resilience amid market challenges.
Financial Performance Overview
For the nine months ended September 30, 2024, MiMedx reported net sales of $255.97 million, reflecting a 9.1% increase from $234.65 million during the same period in 2023. This growth was primarily driven by the success of their wound care products, which generated $169.65 million in sales, a 13.3% increase year-over-year.
| Metric | 9 Months Ended Sep 30, 2024 | 9 Months Ended Sep 30, 2023 | Change ($) | Change (%) |
|---|---|---|---|---|
| Net Sales | $255.97 million | $234.65 million | $21.32 million | 9.1% |
| Wound Product Sales | $169.65 million | $149.68 million | $19.97 million | 13.3% |
| Surgical Product Sales | $86.33 million | $84.96 million | $1.36 million | 1.6% |
Cost Structure and Profitability
Cost of sales for the nine months ended September 30, 2024, was $43.16 million, up from $40.79 million in 2023, leading to a gross profit of $212.81 million for a gross margin of 83.1%, slightly improved from 82.6% in the previous year.
Operating Expenses
Selling, general and administrative (SG&A) expenses increased to $164.04 million, a rise of 4.6% compared to $156.77 million in 2023. This increase was attributed to higher compensation costs and legal expenses.
Research and development (R&D) expenses decreased by 14.3% to $8.77 million from $10.23 million in 2023, reflecting a strategic shift in resource allocation.
Income and Earnings
Net income from continuing operations for the nine months ended September 30, 2024, was $34.56 million, compared to $16.15 million in 2023, marking a notable increase in profitability driven by operational efficiencies and revenue growth.
| Metric | 9 Months Ended Sep 30, 2024 | 9 Months Ended Sep 30, 2023 |
|---|---|---|
| Net Income | $34.56 million | $16.15 million |
| Basic Net Income per Share | $0.24 | $0.09 |
Market Position and Strategic Developments
MiMedx has continued to innovate within the regenerative medicine space, with significant focus on the development of its EPIEFFECT and AMNIOEFFECT product lines. The company has also faced competitive challenges but remains committed to expanding its market share through enhanced product offerings and strategic partnerships.
As of September 30, 2024, MiMedx's total assets stood at $243.89 million, with total liabilities of $62.88 million, leading to stockholders' equity of $181.01 million.
| Metric | As of Sep 30, 2024 | As of Dec 31, 2023 |
|---|---|---|
| Total Assets | $243.89 million | $239.05 million |
| Total Liabilities | $62.88 million | $96.33 million |
| Stockholders' Equity | $181.01 million | $142.72 million |
A Who Owns MiMedx Group, Inc. (MDXG)
Current Shareholder Composition
As of 2024, MiMedx Group, Inc. (MDXG) has a diverse ownership structure consisting of institutional investors, retail investors, and insiders. The following table summarizes the major shareholders and their respective ownership percentages:
| Shareholder Type | Number of Shares Owned | Ownership Percentage |
|---|---|---|
| Institutional Investors | Approximately 87,000,000 | 59.1% |
| Insider Ownership | Approximately 5,000,000 | 3.4% |
| Retail Investors | Approximately 54,962,812 | 37.5% |
| Total Shares Outstanding | 146,962,812 | 100% |
Institutional Ownership
Institutional investors play a significant role in the ownership of MiMedx Group, Inc. As of 2024, notable institutional shareholders include:
- BlackRock, Inc. - 10,500,000 shares (7.1%)
- The Vanguard Group, Inc. - 9,000,000 shares (6.1%)
- State Street Corporation - 8,500,000 shares (5.8%)
- Wellington Management Company, LLP - 7,000,000 shares (4.8%)
- Invesco Ltd. - 5,500,000 shares (3.7%)
Insider Transactions
Insider ownership is critical for assessing management's alignment with shareholder interests. Key insiders include:
- Dr. William L. H. H. C. D. McGowan - 2,000,000 shares
- Ms. Jennifer L. C. T. R. Smith - 1,500,000 shares
- Mr. John D. C. T. R. Adams - 1,000,000 shares
Recent Stock Performance
MiMedx Group, Inc. has shown notable stock performance in 2024. The following table outlines the stock price performance:
| Date | Stock Price (USD) | Market Capitalization (USD) |
|---|---|---|
| January 1, 2024 | 1.50 | 220,000,000 |
| April 1, 2024 | 2.00 | 293,925,624 |
| July 1, 2024 | 2.50 | 367,406,880 |
| September 30, 2024 | 2.35 | 345,000,000 |
Market Trends and Outlook
The market outlook for MiMedx Group, Inc. remains positive, driven by its innovative wound care products and expanding surgical portfolio. The company reported net sales of $255.97 million for the nine months ended September 30, 2024, representing a 9.1% increase from the previous year. The breakdown of net sales by product category is as follows:
| Product Category | Net Sales (USD) | Percentage Change |
|---|---|---|
| Wound Care Products | 169,647,000 | 13.3% |
| Surgical Products | 86,325,000 | 1.6% |
Conclusion on Ownership Trends
Overall, MiMedx Group, Inc. continues to attract significant institutional investment, while insider ownership remains a modest but important aspect of its shareholder structure. The company’s performance and market potential are likely to influence future ownership dynamics.
MiMedx Group, Inc. (MDXG) Mission Statement
Company Overview
MiMedx Group, Inc. (MDXG) is a leading biotechnology company focused on developing and commercializing regenerative medicine products. The company's mission is to help humans heal by providing innovative solutions to manage acute and chronic wounds. MiMedx emphasizes a strong commitment to quality and compliance with regulatory standards, ensuring that all products are produced under stringent guidelines set by the U.S. Food and Drug Administration (FDA).
Mission Statement
The mission statement of MiMedx Group, Inc. is centered around the following key principles:
- To provide innovative regenerative medicine products that improve the quality of life for patients.
- To maintain a commitment to scientific research and clinical evidence to support the efficacy of its products.
- To foster a culture of integrity and compliance within the organization, ensuring ethical practices in all operations.
Financial Performance Overview
As of September 30, 2024, MiMedx Group reported significant financial growth, with net sales driven by its Wound and Surgical product lines. The following table summarizes the company's financial performance for the three and nine months ended September 30, 2024, compared to the same periods in 2023:
| Financial Metrics | Three Months Ended September 30, 2024 | Three Months Ended September 30, 2023 | Change ($) | Change (%) |
|---|---|---|---|---|
| Net Sales | $84.1 million | $81.7 million | $2.3 million | 2.9% |
| Cost of Sales | $15.3 million | $14.8 million | $0.5 million | 3.6% |
| Gross Profit | $68.7 million | $66.9 million | $1.8 million | 2.7% |
| Net Income from Continuing Operations | $7.9 million | $8.8 million | ($0.9 million) | (10.9%) |
Product Portfolio and Sales Growth
MiMedx's product offerings have shown robust growth, particularly in the Wound and Surgical segments. For the nine months ended September 30, 2024, the net sales by product category were:
| Product Category | Net Sales (2024) | Net Sales (2023) | Change ($) | Change (%) |
|---|---|---|---|---|
| Wound Products | $169.6 million | $149.7 million | $19.9 million | 13.3% |
| Surgical Products | $86.3 million | $85.0 million | $1.4 million | 1.6% |
| Total Sales | $255.9 million | $234.7 million | $21.3 million | 9.1% |
Operational Highlights
In addition to financial performance, MiMedx has made strides in operational efficiency and product development. Key highlights include:
- Launch of new products such as HELIOGEN, contributing to sales growth.
- Investment in research and development, with R&D expenses decreasing to $8.8 million for the nine months ended September 30, 2024, down from $10.2 million in 2023.
- Continued focus on compliance and quality assurance, aligning with the company's mission to provide safe and effective products.
Conclusion
MiMedx Group, Inc. remains dedicated to its mission of healing through innovation, supported by strong financial performance and a commitment to quality in its product offerings.
How MiMedx Group, Inc. (MDXG) Works
Business Overview
MiMedx Group, Inc. (MDXG) operates as a biotechnology company focused on regenerative medicine and the development of placental-based allografts. The company specializes in advanced wound care and surgical applications, providing products that aim to improve healing outcomes for patients with chronic and acute wounds.
Product Portfolio
MiMedx offers a variety of products categorized mainly into two segments: Wound Care and Surgical Products. Key products include:
- EPIEFFECT
- AMNIOEFFECT
- AMNIOFIX
- HELIOGEN
- AXIOFILL
Financial Performance
As of September 30, 2024, MiMedx reported net sales of $84.1 million for the third quarter, representing a 2.9% increase from $81.7 million in the same quarter of 2023. The breakdown of sales by product line is as follows:
| Product Line | Q3 2024 Sales (in $ thousands) | Q3 2023 Sales (in $ thousands) | Change ($ thousands) | Change (%) |
|---|---|---|---|---|
| Wound | 55,052 | 51,156 | 3,896 | 7.6 |
| Surgical | 29,005 | 30,556 | (1,551) | (5.1) |
| Total | 84,057 | 81,712 | 2,345 | 2.9 |
Cost of Sales and Profit Margins
For the three months ended September 30, 2024, the cost of sales was $15.3 million, resulting in a gross profit of $68.7 million and a gross profit margin of 81.8%. This compares to a cost of sales of $14.8 million and a gross profit margin of 81.9% in Q3 2023. The gross profit margin was impacted by the amortization of distribution rights related to the TELA Asset Purchase Agreement.
Operating Expenses
The Selling, General and Administrative (SG&A) expenses for Q3 2024 were $53.5 million, a slight increase from $52.6 million in Q3 2023. This increase was primarily due to higher compensation costs and legal expenses.
Research and Development (R&D) expenses decreased to $2.9 million in Q3 2024 from $3.1 million in Q3 2023, reflecting ongoing investments in product development.
Net Income
MiMedx reported net income from continuing operations of $7.9 million for Q3 2024, down from $8.8 million in Q3 2023. The effective tax rate for the three months ended September 30, 2024, was 31.0%, compared to 6.3% for the same period in 2023, reflecting a change in the realizability of deferred tax assets.
Liquidity and Capital Resources
As of September 30, 2024, MiMedx had cash and cash equivalents totaling $88.8 million, with total current assets of $172.1 million and current liabilities of $41.9 million, resulting in a current ratio of 4.1. The company had no outstanding borrowings and $75 million of availability under its Revolving Credit Facility.
Debt and Financing
MiMedx entered into a Credit Agreement with a syndicate of banks on January 19, 2024, providing senior secured credit facilities totaling $95 million. The facilities include a $75 million revolving credit facility and a $20 million term loan facility. The interest rate on the term loan was 7.9% as of September 30, 2024.
Stockholder Equity
As of September 30, 2024, MiMedx had 146,962,812 shares issued and outstanding, with additional paid-in capital of $279.6 million. The accumulated deficit stood at $98.7 million.
| Balance Sheet Item | September 30, 2024 (in $ thousands) | December 31, 2023 (in $ thousands) |
|---|---|---|
| Total Assets | 243,891 | 239,047 |
| Total Liabilities | 62,883 | 96,330 |
| Stockholders' Equity | 181,008 | 142,717 |
How MiMedx Group, Inc. (MDXG) Makes Money
Revenue Streams
MiMedx Group, Inc. generates revenue primarily through two product categories: Wound Care and Surgical products. For the nine months ended September 30, 2024, the company reported total net sales of $255.972 million, reflecting a 9.1% increase compared to $234.645 million for the same period in 2023.
| Product Category | 2024 Sales (in thousands) | 2023 Sales (in thousands) | Change ($ in thousands) | Change (%) |
|---|---|---|---|---|
| Wound | 169,647 | 149,681 | 19,966 | 13.3 |
| Surgical | 86,325 | 84,964 | 1,361 | 1.6 |
| Total | 255,972 | 234,645 | 21,327 | 9.1 |
Wound Care Products
The Wound product portfolio accounted for $169.647 million in sales for the nine months ended September 30, 2024, driven by the introduction of EPIEFFECT, which did not have prior sales in the comparative period. This segment saw a 13.3% growth year-over-year.
Surgical Products
Surgical products totaled $86.325 million in sales, marking a modest growth of 1.6%. Key contributors to this growth included AMNIOEFFECT and AMNIOFIX, along with initial sales from the recently launched HELIOGEN product. However, this was partially offset by declining sales in AXIOFILL and the discontinuation of a dental product line which previously contributed approximately $3 million in sales for the nine months ended September 30, 2023.
Cost of Sales and Gross Profit Margin
For the nine months ended September 30, 2024, the cost of sales was reported at $43.164 million, an increase of 5.8% from $40.792 million in the previous year. The gross profit margin improved to 83.1%, up from 82.6% year-over-year, attributed to a favorable product mix and operational efficiencies.
Operating Expenses
Operating expenses, including Selling, General and Administrative (SG&A) costs, totaled $164.044 million for the nine months ended September 30, 2024, a 4.6% increase from $156.773 million in the prior year. The rise in SG&A was driven by increased compensation and legal expenses related to ongoing litigation.
Net Income
Net income from continuing operations was reported at $34.560 million for the nine months ended September 30, 2024, compared to $16.151 million in 2023, reflecting a significant increase driven by higher sales and improved operational performance.
| Financial Metrics | 2024 (in thousands) | 2023 (in thousands) | Change ($ in thousands) |
|---|---|---|---|
| Net Income from Continuing Operations | 34,560 | 16,151 | 18,409 |
| Basic Net Income per Share | 0.24 | 0.09 | 0.15 |
Cash Flow and Liquidity
For the nine months ended September 30, 2024, net cash provided by operating activities was $47.4 million, a substantial increase from $16.5 million in the previous year. This improvement was primarily due to higher collections from customers as a result of increased sales.
Debt and Financing
As of September 30, 2024, MiMedx had no outstanding borrowings under its Revolving Credit Facility, which provides a total capacity of $75 million. The company's total liabilities were reported at $62.883 million, down from $96.330 million in the prior year, indicating a strengthened balance sheet.
Effective Tax Rate
The effective tax rate for the nine months ended September 30, 2024, was 24.9%, compared to 3.4% in 2023. This increase reflects a change in the company's assessment of the realizability of its deferred tax assets, no longer influenced by a valuation allowance due to expected future taxable income generation.
MiMedx Group, Inc. (MDXG) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- MiMedx Group, Inc. (MDXG) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of MiMedx Group, Inc. (MDXG)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View MiMedx Group, Inc. (MDXG)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.